Memorial Sloan-Kettering Cancer Center's Dr. Howard Scher Reaffirms Commitment To Lead Phase I Trials For AV Therapeutics' Prostate Cancer Drug
5/7/2014 9:30:03 AM
NEW YORK, May 7, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc. ("AV Therapeutics" or the "Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced Howard Scher, MD, Chief, Genitourinary Oncology Service and D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center, reaffirmed his commitment to lead AV Therapeutics' Phase I clinical trial for its prostate cancer immunotherapy drug, Capridine-ß.
Help employers find you! Check out all the jobs and post your resume.
comments powered by